Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study


Cite item

Full Text

Abstract

Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Our trial with participation of 575 patients (mean age 57.73 ± 12.33 years) with arteriogenic erectile dysfunction and great number of vascular risk factors has shown that wardenafil was most popular among our examinees as it is more effective and begins acting faster. Further studies in optimization of the above drugs administration may perfect treatment of erectile dysfuncion.

References

  1. Lue T. F. Erectile dysfunction. N. Engl. J. Med. 2000; 324: 1801-1813.
  2. Montorsi F., Salonia A., Deho F. et al. Pharmacological management of erectile dysfunction. Br. J. Urol. 2003; 91: 446-454.
  3. Francis S. H., Corbin J. D. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. 2003; 4: 457-465.
  4. Tolra J. R., Campana J. M., Ciutat L. F., Miranda E. F. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J. Sex. Med. 2006; 3: 901-919.
  5. Mulhall J. P., McLaughlin T. P., Harnett J. P. et al. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J. Sex. Med. 2005; 2: 848-855.
  6. Rubio-Aurioles E., Porst H., Eardley I. et al. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J. Sex. Med. 2006; 3: 1037-1049.
  7. Mulhall J. P. Understanding erectile dysfunction medication preference studies. Curr. Opin. Urol. 2004; 14: 367-373.
  8. Eardley I.., Rosen R., Fisher W. et al. What men want: desired attributes of ED therapy among men with ED in the MALES 2004 study. J. Sex. Med. 2004; 1 (suppl. 1): 42.
  9. Govier F., Potempa A. J., Kaufman J. et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin. Ther. 2003; 25: 2709-2723.
  10. Keitz A., Rajfer J., Segal S. et al. A multicenter, randomized double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur. Urol. 2004; 45: 499-507.
  11. Stroberg P., Murphy A., Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results o a European multicenter open-label study of patients preference. Clin. Ther. 2003; 25: 2724-2737.
  12. Rotella D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Disciv. 2002; 1: 674-682.
  13. Carson C. C. PDE5 inibibitors: are there differences? Can. J. Urol. 2006; 13 (suppl. 1): 34-39.
  14. Hellstrom W. J., Elhilali M., Homering M. et al. Vardenafil in patients with erectile dysfunction: achieving treatment optimization. J. Androl. 2005; 26: 604-609.
  15. Chia S. J., Ramesh K., Earnest A. Clinical application of prognostic factors for patients with organic causes of erectile dysfunction on 100 mg of sildenafil citrate. Int. J. Urol. 2004; 11: 1104-1109.
  16. Jarow J. P., Burnett A. L., Geringer A. M. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J. Urol. (Baltimore) 1999; 162: 722-725.
  17. Martinez-Jabaloyas J. M., Gil-Salom M., Villamon-Fort R. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur. Urol. 2001; 40: 641-646.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies